Physician profile
Avishek Kumar
NPI 1700171691
$15,794.71
in general payments reported to CMS, 2019-2025
67 companies · $9,980 in 2025
The $9,980 reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $604 · 2021: $670 · 2022: $1,163 · 2023: $1,017 · 2024: $1,426 · 2025: $9,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,708 · Food and Beverage: $4,215 · Honoraria: $2,996 · Education: $497 · Travel and Lodging: $7.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,708.00 |
| Food and Beverage | $4,214.64 |
| Honoraria | $2,996.00 |
| Education | $496.55 |
| Travel and Lodging | $7.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $8,101.13 | 2022-2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $962.53 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Amgen INC. | $646.42 | 2019-2023 | Kyprolis, Vectibix, Nplate |
| Janssen Biotech, INC. | $538.28 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals Lp | $503.17 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Incyte Corporation | $383.61 | 2021-2025 | Jakafi |
| Daiichi Sankyo INC. | $355.07 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Eisai INC. | $274.81 | 2023-2025 | |
| Pfizer INC. | $262.47 | 2019-2025 | |
| Gilead Sciences, INC. | $257.29 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $239.45 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $206.66 | 2023-2025 | Libtayo |
| Seagen INC. | $191.63 | 2020-2024 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $189.80 | 2019-2025 | Iclusig, Ninlaro |
| Sirtex Medical INC | $186.71 | 2025 | Sir-Spheres Microspheres |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avishek Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.